Skip to content

Iovance Biotherapeutics, Inc.

IOVA· NasdaqCore metricsCIK 1425205

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -5.57%
Market cap
$3.53B
462.66M shares
Filings
1,026
$121.47M
Q3 2026+60.6% FY25 yoy
-$22.27M
Q3 2026N/M FY25 yoy
-$23.97M
Q3 2026N/M FY25 yoy
-$154.17M
Q3 2026derivedN/M FY25 yoy
-$0.05
Q3 2026N/M FY25 yoy
$57.93M
Q3 2026+41.0% FY25 yoy
$3.53B
—
9.3×
4.3×
-6.12%
—

Twelve months to Sep 30, 2026 · derived

Price

$7.63+189.02%+$4.99past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$263.50MFY 2025
$263.50M0FY 2010FY 2015FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$263,502,000reported
FY 20242024-12-31$164,070,000reported
FY 20232023-12-31$1,189,000reported
FY 20182018-12-31$0reported
FY 20172017-12-31$0reported
FY 20162016-12-31$0reported
FY 20152015-12-31$0reported
FY 20142014-12-31$0reported
FY 20132013-12-31$0reported
FY 20122012-12-31$0reported
FY 20112011-12-31$0reported
FY 20102010-12-31$0reported

Segments

Revenue by Geography, FY2023 to FY2025FY2023Non-US · FY2023 · $1.19MFY2024Federal income tax · FY2024 · $161.04MNon-US · FY2024 · $3.03MFY2025Federal income tax · FY2025 · $259.01MNon-US · FY2025 · $4.49M
LineFY2025ShareChange
Federal income tax$259.01M98%+60.8%
Non-US$4.49M1.7%+48.3%
Total$263.50M

From the 10-K filed Feb 24, 2026IOVA

Biological products, except diagnostic substances

Iovance Biotherapeutics, Inc. is the 21st largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Iovance Biotherapeutics, Inc. · CIK 1425205 · Engraved from SEC EDGAR